BILIARY TRACT NEOPLASMS IMMUNOTHERAPY
Clinical trials for BILIARY TRACT NEOPLASMS IMMUNOTHERAPY explained in plain language.
Never miss a new study
Get alerted when new BILIARY TRACT NEOPLASMS IMMUNOTHERAPY trials appear
Sign up with your email to follow new studies for BILIARY TRACT NEOPLASMS IMMUNOTHERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail aims to stop bile duct cancer recurrence
Disease control Recruiting nowThis phase II trial tests whether a combination of durvalumab (an immunotherapy), chemotherapy (GEMOX or GC), followed by lenvatinib (a targeted therapy) can prevent biliary tract cancer from coming back after surgery. About 222 adults with bile duct or gallbladder cancer will be…
Matched conditions: BILIARY TRACT NEOPLASMS IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New drug cocktail targets Hard-to-Treat bile duct cancer
Disease control Recruiting nowThis phase II trial is testing a combination of three drugs—trastuzumab rezetecan, adebrelimab, and lenvatinib—as a first treatment for people with advanced or metastatic biliary tract cancer that has HER2 markers. The study aims to see how well the drugs shrink tumors and contro…
Matched conditions: BILIARY TRACT NEOPLASMS IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy hopes to tackle tough bile duct cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy or the targeted drug lenvatinib can help people with advanced biliary tract cancer live longer and control their tumors better. The study will enroll 60 adults whose cancer …
Matched conditions: BILIARY TRACT NEOPLASMS IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC